Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Invested Capital (2020 - 2025)

Historic Invested Capital for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $44.7 million.

  • Ovid Therapeutics' Invested Capital fell 4141.04% to $44.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.7 million, marking a year-over-year decrease of 4141.04%. This contributed to the annual value of $68.2 million for FY2024, which is 2229.12% down from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Invested Capital is $44.7 million, which was down 4141.04% from $55.8 million recorded in Q2 2025.
  • Ovid Therapeutics' Invested Capital's 5-year high stood at $221.1 million during Q1 2021, with a 5-year trough of $44.7 million in Q3 2025.
  • For the 5-year period, Ovid Therapeutics' Invested Capital averaged around $120.4 million, with its median value being $110.7 million (2023).
  • As far as peak fluctuations go, Ovid Therapeutics' Invested Capital soared by 57787.57% in 2021, and later plummeted by 4141.04% in 2025.
  • Over the past 5 years, Ovid Therapeutics' Invested Capital (Quarter) stood at $179.7 million in 2021, then decreased by 26.41% to $132.3 million in 2022, then plummeted by 33.62% to $87.8 million in 2023, then decreased by 22.29% to $68.2 million in 2024, then tumbled by 34.49% to $44.7 million in 2025.
  • Its last three reported values are $44.7 million in Q3 2025, $55.8 million for Q2 2025, and $59.3 million during Q1 2025.